BR112022013892A2 - Anticorpos anti-gal3 e métodos de uso - Google Patents

Anticorpos anti-gal3 e métodos de uso

Info

Publication number
BR112022013892A2
BR112022013892A2 BR112022013892A BR112022013892A BR112022013892A2 BR 112022013892 A2 BR112022013892 A2 BR 112022013892A2 BR 112022013892 A BR112022013892 A BR 112022013892A BR 112022013892 A BR112022013892 A BR 112022013892A BR 112022013892 A2 BR112022013892 A2 BR 112022013892A2
Authority
BR
Brazil
Prior art keywords
cancer
fibrosis
disease
gal3
antibodies
Prior art date
Application number
BR112022013892A
Other languages
English (en)
Portuguese (pt)
Inventor
Sun Dongxu
Rasool Suhail
A Gordon Catherine
Hong Ke
Chen Fan
Matilda Bolin Sara
Shchors Ksenya
Yu Yadong
Tsai Tsung-Huang
A F Williams Samuel
Lala Karan
Wu Heng
Wang Yan
Original Assignee
Truebinding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Truebinding Inc filed Critical Truebinding Inc
Publication of BR112022013892A2 publication Critical patent/BR112022013892A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
BR112022013892A 2020-01-13 2021-01-12 Anticorpos anti-gal3 e métodos de uso BR112022013892A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062960300P 2020-01-13 2020-01-13
US202063024327P 2020-05-13 2020-05-13
US202063092069P 2020-10-15 2020-10-15
US202063122409P 2020-12-07 2020-12-07
PCT/US2021/013136 WO2021146218A1 (en) 2020-01-13 2021-01-12 Anti-gal3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
BR112022013892A2 true BR112022013892A2 (pt) 2022-10-04

Family

ID=76864188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013892A BR112022013892A2 (pt) 2020-01-13 2021-01-12 Anticorpos anti-gal3 e métodos de uso

Country Status (11)

Country Link
US (2) US20230036181A1 (enExample)
EP (1) EP4090685A4 (enExample)
JP (2) JP2023510866A (enExample)
KR (1) KR20220129030A (enExample)
CN (2) CN119930824A (enExample)
AU (1) AU2021207461A1 (enExample)
BR (1) BR112022013892A2 (enExample)
CA (1) CA3166552A1 (enExample)
IL (1) IL294486A (enExample)
MX (1) MX2022008450A (enExample)
WO (1) WO2021146218A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN115279789A (zh) * 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
JP2024526764A (ja) * 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
WO2024073511A2 (en) * 2022-09-28 2024-04-04 Truebinding, Inc. Therapies with anti-gal3 antibodies
JP2026523670A (ja) * 2024-03-08 2026-07-14 サンメッド セラピューティック リミテッド 抗ガレクチン３抗体ならびに癲癇および関連疾患におけるその使用
CN118286392A (zh) * 2024-03-28 2024-07-05 广州医科大学附属妇女儿童医疗中心 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用
WO2025240949A1 (en) * 2024-05-17 2025-11-20 The Administrators Of The Tulane Educational Fund Compositions and methods for the treatment of idiopathic pulmonary fibrosis
WO2025264872A1 (en) * 2024-06-21 2025-12-26 Truebinding, Inc. Methods and compositions for treating neurodevelopmental disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101222281B1 (ko) * 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
MX2010005282A (es) * 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
US8349579B2 (en) * 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
BRPI0919975A2 (pt) * 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
CN103443125B (zh) * 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
AU2014370393B2 (en) * 2013-12-27 2018-09-20 Eliaz Therapeutics, Inc. Plasmapheresis device
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN111201030B (zh) * 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP7539834B2 (ja) * 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
WO2019165421A1 (en) * 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Diagnostic methods using anti-muc1* antibodies
KR20210124308A (ko) * 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도

Also Published As

Publication number Publication date
JP2025163070A (ja) 2025-10-28
KR20220129030A (ko) 2022-09-22
AU2021207461A1 (en) 2022-09-01
CN119930824A (zh) 2025-05-06
EP4090685A1 (en) 2022-11-23
IL294486A (en) 2022-09-01
US20250145722A1 (en) 2025-05-08
WO2021146218A1 (en) 2021-07-22
CN115427449A (zh) 2022-12-02
US20230036181A1 (en) 2023-02-02
MX2022008450A (es) 2022-12-13
EP4090685A4 (en) 2024-12-18
CA3166552A1 (en) 2021-07-22
JP2023510866A (ja) 2023-03-15

Similar Documents

Publication Publication Date Title
MX2022008450A (es) Anticuerpos anti-gal3 y metodos de uso.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
Garcia-Romero et al. Extracellular vesicles compartment in liquid biopsies: Clinical application
WO2019224025A3 (en) Antagonizing cd73 antibody
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2017177149A3 (en) Methods and compositions for car t cell therapy
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
BR0108646A (pt) Polipeptìdeo, molécula de ácido nucleico, e, método para matar uma célula que carrega um antìgeno
WO2014081944A9 (en) Egfr and c-met-fibronectin type iii domain binding molecules
WO2015053871A8 (en) NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
EA201790986A1 (ru) Антитела к cd73 и их применения
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2007101227A8 (en) Identification and use of novopeptides for the treatment of cancer
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2007038637A3 (en) Human monoclonal antibodies to cd70
BR0115260A (pt) Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças
MX358321B (es) Anticuerpos anti-ceacam5 y usos de los mismos.
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
Ham et al. Molecular tumor targeting of gelonin by fusion with F3 peptide
WO2006053110A3 (en) Ovr110 antibody compositions and methods of use
TW200613733A (en) Use of cyanine dyes for the diagnosis of disease associated with angiogenesis